Skip to main content
STTK
NASDAQ Life Sciences

Director (OrbiMed) Purchases $5.0M in Pre-Funded Warrants

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$4.68
Mkt Cap
$355.031M
52W Low
$0.712
52W High
$8.33
52W Position info
557% above low
Off High info
44% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

STTK has more than doubled off its 52-week low of $0.712.

Summary

A director associated with institutional investor OrbiMed Advisors purchased approximately $5.0 million in pre-funded warrants, indicating strong institutional confidence in Shattuck Labs.


Key Events · Ownership and Investor Activity · STTK

  • Significant Institutional Investment

    Mona Ashiya, a director representing OrbiMed Advisors, acquired 1,250,000 pre-funded warrants for approximately $5.0 million.

  • Follows Recent Public Offering

    This purchase occurred on June 11, 2026, as part of a public offering that closed on the same day, where pre-funded warrants were priced at $3.9999 each.

  • Strong Vote of Confidence

    The substantial investment by a major institutional shareholder with a board seat signals strong conviction in Shattuck Labs' valuation and clinical pipeline, particularly after recent positive Phase 1 trial results for SL-325.


Analysis · STTK · Life Sciences

Mona Ashiya, a director representing OrbiMed Advisors, acquired approximately $5.0 million worth of pre-funded warrants. This significant investment by a major institutional shareholder, especially following a recent public offering and positive clinical trial results, signals strong confidence in the company's future prospects and valuation.

How filings like this one have moved

In the 30 days to Sep 16, 2026, 39.8% of the 397 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, STTK was trading at $4.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $355M. The 52-week trading range was $0.71 to $8.33. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

STTK - Latest Insights

STTK
Aug 11, 2026, 6:59 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $6.08 info
Change: -$0.920 (-13%) info
Market Cap: $610.209M info
STTK
Aug 11, 2026, 6:57 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $6.08 info
Change: -$0.920 (-13%) info
Market Cap: $610.209M info
STTK
Aug 11, 2026, 6:25 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $6.08 info
Change: -$0.920 (-13%) info
Market Cap: $610.209M info
STTK
Jul 17, 2026, 9:30 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $7.09
Real-time Price: $6.08 info
Change: -$1.01 (-14%) info
Market Cap: $610.209M info
STTK
Jun 15, 2026, 6:12 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $4.68
Real-time Price: $6.08 info
Change: +$1.40 (+30%) info
Market Cap: $610.209M info